These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
648 related articles for article (PubMed ID: 31790940)
41. Treatment of status epilepticus: a survey of neurologists. Claassen J; Hirsch LJ; Mayer SA J Neurol Sci; 2003 Jul; 211(1-2):37-41. PubMed ID: 12767495 [TBL] [Abstract][Full Text] [Related]
42. Treatment of established status epilepticus in the elderly - a study protocol for a prospective multicenter double-blind comparative effectiveness trial (ToSEE). Müller A; Schmiedeknecht A; Mende M; Awissus C; Rosenow F; Hamer H; Classen J BMC Neurol; 2020 Dec; 20(1):438. PubMed ID: 33272223 [TBL] [Abstract][Full Text] [Related]
43. Predictors of outcome in refractory status epilepticus. Hocker SE; Britton JW; Mandrekar JN; Wijdicks EF; Rabinstein AA JAMA Neurol; 2013 Jan; 70(1):72-7. PubMed ID: 23318514 [TBL] [Abstract][Full Text] [Related]
44. Causes and outcomes of new onset status epilepticus and predictors of refractoriness to therapy. Jayalakshmi S; Vooturi S; Sahu S; Yada PK; Mohandas S J Clin Neurosci; 2016 Apr; 26():89-94. PubMed ID: 26822381 [TBL] [Abstract][Full Text] [Related]
45. Episodes of status epilepticus in young adults: etiologic factors, subtypes, and outcomes. Ozdilek B; Midi I; Agan K; Bingol CA Epilepsy Behav; 2013 May; 27(2):351-4. PubMed ID: 23537621 [TBL] [Abstract][Full Text] [Related]
46. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Rohracher A; Höfler J; Kalss G; Leitinger M; Kuchukhidze G; Deak I; Dobesberger J; Novak H; Pilz G; Zerbs A; Trinka E Epilepsy Behav; 2015 Aug; 49():354-8. PubMed ID: 25962657 [TBL] [Abstract][Full Text] [Related]
47. Early predictors of refractory status epilepticus: an international two-center study. Sutter R; Kaplan PW; Marsch S; Hammel EM; Rüegg S; Ziai WC Eur J Neurol; 2015 Jan; 22(1):79-85. PubMed ID: 25104078 [TBL] [Abstract][Full Text] [Related]
48. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Delaj L; Novy J; Ryvlin P; Marchi NA; Rossetti AO Acta Neurol Scand; 2017 Jan; 135(1):92-99. PubMed ID: 27080243 [TBL] [Abstract][Full Text] [Related]
49. Clinical presentation of new onset refractory status epilepticus in children (the pSERG cohort). Sculier C; Barcia Aguilar C; Gaspard N; Gaínza-Lein M; Sánchez Fernández I; Amengual-Gual M; Anderson A; Arya R; Burrows BT; Brenton JN; Carpenter JL; Chapman KE; Clark J; Gaillard WD; Glauser TA; Goldstein JL; Goodkin HP; Gorman M; Lai YC; McDonough TL; Mikati MA; Nayak A; Peariso K; Riviello J; Rusie A; Sperberg K; Stredny CM; Tasker RC; Tchapyjnikov D; Vasquez A; Wainwright MS; Wilfong AA; Williams K; Loddenkemper T; Epilepsia; 2021 Jul; 62(7):1629-1642. PubMed ID: 34091885 [TBL] [Abstract][Full Text] [Related]
50. Refractory Status Epilepticus: Risk Factors and Analysis of Intubation in the Multicenter SENSE Registry. Beuchat I; Rosenow F; Kellinghaus C; Trinka E; Unterberger I; Rüegg S; Sutter R; Tilz C; Uzelac Z; Rossetti AO; Strzelczyk A Neurology; 2022 Oct; 99(16):e1824-e1834. PubMed ID: 35948449 [TBL] [Abstract][Full Text] [Related]
51. A comparison of four antiepileptic drugs in status epilepticus: experience from India. Misra UK; Kalita J Int J Neurosci; 2016 Nov; 126(11):1013-9. PubMed ID: 26456955 [TBL] [Abstract][Full Text] [Related]
52. Meta-analysis and cost-effectiveness of second-line antiepileptic drugs for status epilepticus. Sánchez Fernández I; Gaínza-Lein M; Lamb N; Loddenkemper T Neurology; 2019 May; 92(20):e2339-e2348. PubMed ID: 31068480 [TBL] [Abstract][Full Text] [Related]
53. Clinical characteristics and treatment approach of established New-Onset status epilepticus (eNOSE): A Real-World multicenter experience. Dono F; Evangelista G; Rodorigo D; Rollo E; Romozzi M; Corniello C; Liviello D; Dasara M; Capriati L; Quintieri P; Servidei S; Della Marca G; Calabresi P; Sensi SL; Vollono C Epilepsy Behav; 2024 Oct; 159():109951. PubMed ID: 39111103 [TBL] [Abstract][Full Text] [Related]
54. Treatment of refractory and superrefractory status epilepticus with topiramate: A cohort study of 106 patients and a review of the literature. Fechner A; Hubert K; Jahnke K; Knake S; Konczalla J; Menzler K; Ronellenfitsch MW; Rosenow F; Strzelczyk A Epilepsia; 2019 Dec; 60(12):2448-2458. PubMed ID: 31713232 [TBL] [Abstract][Full Text] [Related]
55. Inadequate benzodiazepine dosing may result in progression to refractory and non-convulsive status epilepticus. Rao SK; Mahulikar A; Ibrahim M; Shah A; Seraji-Bozorgzad N; Mohamed W Epileptic Disord; 2018 Aug; 20(4):265-269. PubMed ID: 30113012 [TBL] [Abstract][Full Text] [Related]
56. Identification of Risk Factors for Refractory Status Epilepticus. Tatro HA; Hamilton LA; Peters C; Rowe AS Ann Pharmacother; 2020 Jan; 54(1):14-21. PubMed ID: 31347376 [No Abstract] [Full Text] [Related]
57. Vagus nerve stimulation in refractory and super-refractory status epilepticus - A systematic review. Dibué-Adjei M; Brigo F; Yamamoto T; Vonck K; Trinka E Brain Stimul; 2019; 12(5):1101-1110. PubMed ID: 31126871 [TBL] [Abstract][Full Text] [Related]
58. Induction of burst suppression or coma using intravenous anesthetics in refractory status epilepticus. Kang BS; Jung KH; Shin JW; Moon JS; Byun JI; Lim JA; Moon HJ; Kim YS; Lee ST; Chu K; Lee SK J Clin Neurosci; 2015 May; 22(5):854-8. PubMed ID: 25744078 [TBL] [Abstract][Full Text] [Related]
59. Critical Care Management of Status Epilepticus at a Tertiary Care University Hospital. Mahmoud SH; Marette V; Lindqvist T; Ahmed SN Can J Neurol Sci; 2019 Nov; 46(6):702-710. PubMed ID: 31554529 [TBL] [Abstract][Full Text] [Related]
60. Intravenous Corticosteroids as an Adjunctive Treatment for Refractory and Super-Refractory Status Epilepticus: An Observational Cohort Study. Pantazou V; Novy J; Rossetti AO CNS Drugs; 2019 Feb; 33(2):187-192. PubMed ID: 30627972 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]